{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T01:40:28Z","timestamp":1782351628752,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Synthetic cannabinoids (SC) are chemical substances which activate cannabinoid receptors similarly to tetrahydrocannabinol, but with a higher efficacy. These substances are used as illicit recreational drugs, often smoked as herbal mixtures. The continuing availability and rapid evolution of SC is an ongoing health risk. The adverse effects of SC are wide ranging, and span from mild behavioral changes to death. Knowledge regarding gastrointestinal (GI) manifestations of SC use is sparse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Single tertiary-care referral medical center retrospective study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The medical records of patients presented to hospital emergency care due to SC use between January 2014 and February 2018 were retrieved from Hadassah Mount Scopus Hospital\u2019s computerized database. The records were reviewed for clinical outcomes and laboratory tests. Fifty-five (55) patients were identified with a hospital presentation due to SC use. Twenty-one (21) out of 55 patients (38%) reported gastrointestinal complaints. The most common complaints were abdominal pain and vomiting. Of those, 28% had recurrent emergency department presentations due to abdominal pain and 66% presented with leukocytosis. Serum lactate was elevated in 66% of patients with GI manifestations. One patient had an abnormal computerized tomography (CT) abdominal angiography scan, which was compatible with intestinal ischemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The clinical spectrum of gastrointestinal manifestations in SC intoxication ranges from mild symptoms, such as abdominal pain and vomiting, to even more severe symptoms suggestive of intestinal ischemia. Clinicians should be aware that abdominal pain and other gastrointestinal complaints can be associated with SC use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-021-01847-w","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T06:05:06Z","timestamp":1625551506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Gastrointestinal manifestations of synthetic cannabinoids: a retrospective cohort study"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9769-4621","authenticated-orcid":false,"given":"David","family":"Hakimian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel A.","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawfik","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Massarwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Israel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaden","family":"Salameh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonatan","family":"Gershinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barak","family":"Shapira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mordechai","family":"Muszkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,6]]},"reference":[{"issue":"1-2","key":"1847_CR1","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.drugalcdep.2012.12.011","volume":"131","author":"AR Winstock","year":"2013","unstructured":"Winstock AR, Barratt MJ. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend. 2013;131(1\u20132):106\u201311.","journal-title":"Drug Alcohol Depend"},{"key":"1847_CR2","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.drugalcdep.2015.01.044","volume":"149","author":"JJ Palamar","year":"2015","unstructured":"Palamar JJ, Acosta P. Synthetic cannabinoid use in a nationally representative sample of US high school seniors. Drug Alcohol Depend. 2015;149:194\u2013202.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"1847_CR3","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1124\/jpet.113.206003","volume":"346","author":"LK Brents","year":"2013","unstructured":"Brents LK, et al. Differential drug\u2013drug interactions of the synthetic cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy. J Pharmacol Expl Therap. 2013;346(3):350\u201361.","journal-title":"J Pharmacol Expl Therap"},{"issue":"1","key":"1847_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.lfs.2013.07.023","volume":"97","author":"CL German","year":"2014","unstructured":"German CL, Fleckenstein AE, Hanson GR. Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life Sci. 2014;97(1):2\u20138.","journal-title":"Life Sci"},{"issue":"3","key":"1847_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.toxlet.2010.06.002","volume":"197","author":"I Vardakou","year":"2010","unstructured":"Vardakou I, Pistos C, Spiliopoulou Ch. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett. 2010;197(3):157\u201362.","journal-title":"Toxicol Lett"},{"key":"1847_CR6","doi-asserted-by":"crossref","unstructured":"Kalk NJ, et al. Spice and all things nasty: the challenge of synthetic cannabinoids. 2016: i5639.\u200f","DOI":"10.1136\/bmj.i5639"},{"issue":"1","key":"1847_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/15563650.2015.1110590","volume":"54","author":"RJ Tait","year":"2016","unstructured":"Tait RJ, et al. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol. 2016;54(1):1\u201313.","journal-title":"Clin Toxicol"},{"issue":"2","key":"1847_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/dta.220","volume":"3","author":"C Cole","year":"2011","unstructured":"Cole C, et al. Adulterants in illicit drugs: a review of empirical evidence. Drug Test Anal. 2011;3(2):89\u201396.","journal-title":"Drug Test Anal"},{"issue":"1482","key":"1847_CR9","first-page":"6","volume":"131","author":"C Wilkins","year":"2018","unstructured":"Wilkins C, Rychert M. Responding to a new wave of high potency synthetic cannabinoids. N Zeal Med J (Online). 2018;131(1482):6\u20139.","journal-title":"N Zeal Med J (Online)"},{"key":"1847_CR10","doi-asserted-by":"crossref","unstructured":"Gilley M, et al. Synthetic cannabinoid exposure in adolescents presenting for emergency care. Pediatric Emergency Care 2018.","DOI":"10.1097\/PEC.0000000000001454"},{"issue":"9","key":"1847_CR11","doi-asserted-by":"publisher","first-page":"e13370","DOI":"10.1111\/nmo.13370","volume":"30","author":"M Camilleri","year":"2018","unstructured":"Camilleri M. Cannabinoids and gastrointestinal motility: pharmacology, clinical effects, and potential therapeutics in humans. Neurogastroenterol Motility. 2018;30(9):e13370.","journal-title":"Neurogastroenterol Motility"},{"issue":"1","key":"1847_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1432-1033.1995.tb20780.x","volume":"232","author":"S Gali\u00e8gue","year":"1995","unstructured":"Gali\u00e8gue S, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232(1):54\u201361.","journal-title":"Eur J Biochem"},{"issue":"4","key":"1847_CR13","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jemermed.2012.11.034","volume":"45","author":"CY Hopkins","year":"2013","unstructured":"Hopkins CY, Gilchrist BL. A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids. J Emerg Med. 2013;45(4):544\u20136.","journal-title":"J Emerg Med"},{"key":"1847_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.drugalcdep.2014.08.005","volume":"144","author":"MS Castaneto","year":"2014","unstructured":"Castaneto MS, et al. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014;144:12\u201341.","journal-title":"Drug Alcohol Depend"},{"key":"1847_CR15","doi-asserted-by":"crossref","unstructured":"Hakimian D, et al. Fatal mesenteric ischemia induced by synthetic cannabinoids: a case report and literature review. Case Rep Emergency Med. 2017.","DOI":"10.1155\/2017\/6964078"},{"issue":"3","key":"1847_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nrcardio.2017.130","volume":"15","author":"P Pacher","year":"2018","unstructured":"Pacher P, et al. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nat Rev Cardiol. 2018;15(3):151.","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"1847_CR17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa1610300","volume":"376","author":"AJ Adams","year":"2017","unstructured":"Adams AJ, et al. Zombie\u201d outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. New Engl J Med. 2017;376(3):235\u201342.","journal-title":"New Engl J Med"},{"issue":"3","key":"1847_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1124\/pr.58.3.2","volume":"58","author":"P Pacher","year":"2006","unstructured":"Pacher P, B\u00e1tkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389\u2013462.","journal-title":"Pharmacol Rev"},{"issue":"3","key":"1847_CR19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.tips.2016.12.003","volume":"38","author":"BM Ford","year":"2017","unstructured":"Ford BM, et al. Synthetic pot: not your grandfather\u2019s marijuana. Trends Pharmacol Sci. 2017;38(3):257\u201376.","journal-title":"Trends Pharmacol Sci"},{"issue":"13","key":"1847_CR20","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1212\/WNL.0000000000001973","volume":"85","author":"DZ Rose","year":"2015","unstructured":"Rose DZ, et al. Hemorrhagic stroke following use of the synthetic marijuana \u201cspice.\u201d Neurology. 2015;85(13):1177\u20139.","journal-title":"Neurology"},{"issue":"6","key":"1847_CR21","doi-asserted-by":"publisher","first-page":"e1622","DOI":"10.1542\/peds.2010-3823","volume":"128","author":"A Mir","year":"2011","unstructured":"Mir A, et al. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics. 2011;128(6):e1622\u20137.","journal-title":"Pediatrics"},{"issue":"1","key":"1847_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s13181-016-0595-z","volume":"13","author":"CJ Sorensen","year":"2017","unstructured":"Sorensen CJ, et al. Cannabinoid hyperemesis syndrome: diagnosis, pathophysiology, and treatment\u2014a systematic review. J Med Toxicol. 2017;13(1):71\u201387.","journal-title":"J Med Toxicol"},{"issue":"3","key":"1847_CR23","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/j.1360-0443.2012.04078.x","volume":"108","author":"M Hermanns-Clausen","year":"2013","unstructured":"Hermanns-Clausen M, Kneisel S, Szabo B, Auw\u00e4rter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction. 2013;108(3):534\u201344.","journal-title":"Addiction"},{"issue":"3","key":"1847_CR24","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jemermed.2017.12.010","volume":"54","author":"JR Richards","year":"2018","unstructured":"Richards JR. Cannabinoid hyperemesis syndrome: pathophysiology and treatment in the emergency department. J Emerg Med. 2018;54(3):354\u201363.","journal-title":"J Emerg Med"},{"key":"1847_CR25","doi-asserted-by":"crossref","unstructured":"Wood DM, Ceronie B, Dargan PI. Healthcare professionals are less confident in managing acute toxicity related to the use of new psychoactive substances (nps) compared with classical recreational drugs. QJM: Month J Assoc Physic. 2016;109(8), 527\u201329.","DOI":"10.1093\/qjmed\/hcv208"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01847-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-021-01847-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01847-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T06:17:30Z","timestamp":1625552250000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-021-01847-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,6]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1847"],"URL":"https:\/\/doi.org\/10.1186\/s12876-021-01847-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-54002\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-54002\/v2","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,6]]},"assertion":[{"value":"29 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Hadassah Medical Center Institutional Review Board. This study does not involve any studies with human participants or animals which were performed by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest and competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"274"}}